Yea the first question asked was about the burns trial. James almost seemed annoyed about answering it - maybe he's getting lots of emails.
He said it was a blinded trial and they aren't meant to hear about the results until the end of the trial. Through some negotiation they managed to get some early results from the trial to pass on to shareholders (the ones announced ages ago).
But I don't see why they can't update us as to number of patients recruited/treated/completed. Shareholders deserve to be kept abreast of trial progress.
The slide on the burns study seemed to indicate that it is somewhat complete and they are analysing the data now.
RCE Price at posting:
68.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)